Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Antonia · SciRah

Researcher profile · Semantic Scholar

S. Antonia

Share profile

S. Antonia — researcher profile on SciRah

h-index: 91
Works: 431
Citations: 71K

Most-cited papers

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
D. Spigel, C. Faivre-Finn, J. Gray, D. Vicente +21 more
2022Journal of Clinical Oncology1,091 citations Open access
Semantic Scholar
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
P. Baas, A. Scherpereel, A. Nowak, Nobukazu Fujimoto +17 more
2021The Lancet920 citations Open access
Semantic Scholar
Tumor Mutation Burden and Efficacy of Nivolumab Monotherapy and in Combination With Ipilimumab in Small Cell Lung Cancer
M. Hellmann, M. Callahan, M. Awad, E. Calvo +12 more
2018Cancer Cell771 citations Open access
Semantic Scholar
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer
N. Rizvi, B. Cho, N. Reinmuth, K. Lee +26 more
2020JAMA Oncology553 citations Open access
Semantic Scholar
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab
S. Topalian, F. Hodi, J. Brahmer, S. Gettinger +16 more
2019JAMA Oncology544 citations Open access
Semantic Scholar
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer
H. Borghaei, S. Gettinger, E. Vokes, L. Chow +26 more
2021Journal of Clinical Oncology512 citations Open access
Semantic Scholar
Brief report: Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC - an update from the PACIFIC trial.
C. Faivre-Finn, D. Vicente, T. Kurata, D. Planchard +19 more
2021Journal of Thoracic Oncology397 citations Open access
Semantic Scholar
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
J. Gray, A. Villegas, D. Daniel, D. Vicente +16 more
2019Journal of Thoracic Oncology380 citations Open access
Semantic Scholar
Tumor-infiltrating lymphocyte treatment for anti-PD-1 resistant metastatic lung cancer: a phase I trial
B. Creelan, chao wang, J. Teer, E. Toloza +22 more
2021Nature Medicine379 citations Open access
Semantic Scholar
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis
S. Antonia, H. Borghaei, S. Ramalingam, L. Horn +16 more
2019The Lancet Oncology291 citations Open access
Semantic Scholar
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort.
N. Ready, P. Ott, M. Hellmann, J. Zugazagoitia +16 more
2020Journal of Thoracic Oncology275 citations Open access
Semantic Scholar
Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies.
A. Passaro, J. Brahmer, S. Antonia, T. Mok +1 more
2022Journal of Clinical Oncology269 citations
Semantic Scholar
Second-Line Nivolumab in Relapsed Small-Cell Lung Cancer: CheckMate 331.
D. Spigel, D. Vicente, T. Ciuleanu, S. Gettinger +18 more
2021Annals of Oncology257 citations Open access
Semantic Scholar
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial
L. Paz-Ares, A. Spira, D. Raben, D. Planchard +17 more
2020Annals of Oncology207 citations Open access
Semantic Scholar
Patient-derived micro-organospheres (MOS) enable clinical precision oncology
S. Ding, Carolyn Hsu, Zhaohui Wang, Naveen R. Natesh +33 more
2022Cell Stem Cell204 citations Open access
Semantic Scholar
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.
M. Hellmann, M. Callahan, M. Awad, E. Calvo +12 more
2019Cancer Cell142 citations Open access
Semantic Scholar
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial
C. Aggarwal, A. Prawira, S. Antonia, O. Rahma +25 more
2022Journal for ImmunoTherapy of Cancer141 citations Open access
Semantic Scholar
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.
R. Hui, M. Özgüroğlu, A. Villegas, D. Daniel +14 more
2019The Lancet Oncology135 citations Open access
Semantic Scholar
Sirt2 Inhibition Enhances Metabolic Fitness and Effector Functions of Tumor-Reactive T cells
I. Hamaidi, Lin Zhang, Nayoung Kim, Min-Hsuan Wang +13 more
2020Cell Metabolism124 citations Open access
Semantic Scholar
The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management
M. Girotra, A. Hansen, A. Farooki, D. Byun +8 more
2018JNCI Cancer Spectrum116 citations Open access
Semantic Scholar
The NKG2A immune checkpoint — a new direction in cancer immunotherapy
B. Creelan, S. Antonia
2019Nature Reviews Clinical Oncology103 citations
Semantic Scholar
Phase 1/1b study of pembrolizumab plus vorinostat in advanced/metastatic non-small cell lung cancer
J. Gray, A. Saltos, T. Tanvetyanon, E. Haura +13 more
2019Clinical Cancer Research102 citations Open access
Semantic Scholar
Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma
R. Hassan, E. Alley, H. Kindler, S. Antonia +15 more
2019Clinical Cancer Research102 citations Open access
Semantic Scholar
Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-mutant NSCLC: A Post-Hoc Subgroup Analysis from PACIFIC.
J. Naidoo, S. Antonia, Yi-Long Wu, B. Cho +4 more
2023Journal of Thoracic Oncology101 citations Open access
Semantic Scholar
Interaction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade in a United States cohort
Rachel C. Newsome, R. Gharaibeh, C. Pierce, Wildson Vieira da Silva +7 more
2022Genome Medicine96 citations Open access
Semantic Scholar
Clinical Activity, Tolerability, and Long-term Follow-up of Durvalumab in Patients With Advanced NSCLC.
S. Antonia, A. Balmanoukian, J. Brahmer, S. Ou +27 more
2019Journal of Thoracic Oncology90 citations Open access
Semantic Scholar
Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small cell lung cancer
A. Schoenfeld, S. Antonia, M. Awad, E. Felip +14 more
2021Annals of Oncology89 citations Open access
Semantic Scholar
Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial.
D. Spigel, C. Faivre-Finn, J. Gray, D. Vicente +16 more
202186 citations
Semantic Scholar
Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort.
N. Segal, S. Ou, A. Balmanoukian, M. Fury +16 more
2019European Journal of Cancer80 citations
Semantic Scholar
Abstract CT074: Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): Blood and tissue TMB analysis from MYSTIC, a Phase III study of first-line durvalumab ± tremelimumab vs chemotherapy.
S. Peters, B. Cho, N. Reinmuth, K. Lee +18 more
2019Clinical Trials78 citations
Semantic Scholar
Systematic review of combinations of targeted or immunotherapy in advanced solid tumors
A. Tan, S. Bagley, P. Wen, M. Lim +17 more
2021Journal for ImmunoTherapy of Cancer76 citations Open access
Semantic Scholar
IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cells
L. L. Remsing Rix, N. Sumi, Q. Hu, Bina Desai +13 more
2022Science Signaling72 citations Open access
Semantic Scholar
A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer
E. Nadal, M. Saleh, S. Aix, M. Ochoa de Olza +13 more
2023BMC Cancer63 citations Open access
Semantic Scholar
Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer
A. Chiappori, Charles C. Williams, J. Gray, T. Tanvetyanon +8 more
2018Cancer Immunology and Immunotherapy63 citations Open access
Semantic Scholar
Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC).
M. Socinski, M. Özgüroğlu, A. Villegas, D. Daniel +10 more
2021Clinical Lung Cancer58 citations Open access
Semantic Scholar
Phase I study of taminadenant (PBF509/NIR178), an adenosine 2A receptor antagonist, with or without spartalizumab, in patients with advanced non-small cell lung cancer
A. Chiappori, B. Creelan, T. Tanvetyanon, J. Gray +14 more
2022Clinical Cancer Research50 citations Open access
Semantic Scholar
A Gene Mutation Signature Predicting Immunotherapy Benefits in Non-Small Cell Lung Cancer Patients
Dong Pan, Angela Hu, S. Antonia, Chuan-Yuan Li
2020Journal of Thoracic Oncology50 citations Open access
Semantic Scholar
Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC).
C. Faivre-Finn, D. Spigel, S. Senan, C. Langer +12 more
2020Lung Cancer49 citations Open access
Semantic Scholar
Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival.
Patrick C. Kellish, Daniil E. Shabashvili, Masmudur M. Rahman, Akbar Nawab +13 more
2019Journal of Clinical Investigation48 citations Open access
Semantic Scholar
ID:2908 First-Line Nivolumab + Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743
P. Baas, A. Scherpereel, A. Nowak, N. Fujimoto +16 more
202044 citations Open access
Semantic Scholar
Phase I/II study of the A2AR antagonist NIR178 (PBF-509), an oral immunotherapy, in patients (pts) with advanced NSCLC.
A. Chiappori, Charles C. Williams, B. Creelan, T. Tanvetyanon +13 more
201842 citations
Semantic Scholar
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
R. Govindan, C. Aggarwal, S. Antonia, M. Davies +18 more
2022Journal for ImmunoTherapy of Cancer39 citations Open access
Semantic Scholar
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Reply.
S. Antonia
2019New England Journal of Medicine39 citations
Semantic Scholar
Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC.
C. Faivre-Finn, D. Spigel, S. Senan, C. Langer +13 more
2018Annals of Oncology34 citations Open access
Semantic Scholar
Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial.
J. Naidoo, J. Vansteenkiste, C. Faivre-Finn, M. Özgüroğlu +7 more
2022Lung Cancer29 citations Open access
Semantic Scholar
First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.
A. Scherpereel, S. Antonia, Y. Bautista, F. Grossi +15 more
2022Lung Cancer28 citations Open access
Semantic Scholar
Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance
B. Creelan, J. Gray, T. Tanvetyanon, A. Chiappori +4 more
2019British Journal of Cancer25 citations Open access
Semantic Scholar
Three-year overall survival update from the PACIFIC trial.
J. Gray, A. Villegas, D. Daniel, D. Vicente +16 more
2019Journal of Clinical Oncology22 citations
Semantic Scholar
Abstract CT056: Durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes (TIL) in non-small cell lung cancer (NSCLC): A phase I trial
B. Creelan, chao wang, J. Teer, E. Toloza +17 more
2020Tumor Biology18 citations
Semantic Scholar
Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC
M. Lind, S. Gettinger, H. Borghaei, J. Brahmer +27 more
202018 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

D. Vicente×13
Invite
D. Vicente — researcher profile on SciRah
J. Gray×12
Invite
J. Gray — researcher profile on SciRah
D. Spigel×11
Invite
D. Spigel — researcher profile on SciRah
C. Faivre-Finn×10
Invite
C. Faivre-Finn — researcher profile on SciRah

×10

Invite

R. Hui — researcher profile on SciRah

Invite

B. Creelan — researcher profile on SciRah

M. Özgüroğlu×9

Invite

M. Özgüroğlu — researcher profile on SciRah

Invite

B. Cho — researcher profile on SciRah

A. Chiappori×9

Invite

A. Chiappori — researcher profile on SciRah

Invite

L. Paz-Ares — researcher profile on SciRah

Invite

K. Lee — researcher profile on SciRah

Invite

E. Haura — researcher profile on SciRah